These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21257797)

  • 41. A Regression Approach to Visual Predictive Checks for Population Pharmacometric Models.
    Jamsen KM; Patel K; Nieforth K; Kirkpatrick CMJ
    CPT Pharmacometrics Syst Pharmacol; 2018 Oct; 7(10):678-686. PubMed ID: 30058222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multinomial logistic functions in markov chain models of sleep architecture: internal and external validation and covariate analysis.
    Bizzotto R; Zamuner S; Mezzalana E; De Nicolao G; Gomeni R; Hooker AC; Karlsson MO
    AAPS J; 2011 Sep; 13(3):445-63. PubMed ID: 21691915
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modeling of bounded outcome scores with data on the boundaries: application to disability assessment for dementia scores in Alzheimer's disease.
    Xu XS; Samtani M; Yuan M; Nandy P
    AAPS J; 2014 Nov; 16(6):1271-81. PubMed ID: 25165039
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Conditioning on certain random events associated with statistical variability in PK/PD.
    Beal SL
    J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):213-43. PubMed ID: 16283533
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Why should prediction discrepancies be renamed standardized visual predictive check?
    Comets E; Brendel K; Mentré F
    J Clin Pharmacol; 2012 Aug; 52(8):1284-5; author reply 1286-7. PubMed ID: 21908878
    [No Abstract]   [Full Text] [Related]  

  • 46. Development of visual predictive checks accounting for multimodal parameter distributions in mixture models.
    Arshad U; Chasseloup E; Nordgren R; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):241-250. PubMed ID: 30968312
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Automatic data binning for improved visual diagnosis of pharmacometric models.
    Lavielle M; Bleakley K
    J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):861-71. PubMed ID: 22042498
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of simulated cumulative drug versus time data sets with indices.
    Vertzoni M; Symillides M; Iliadis A; Nicolaides E; Reppas C
    Eur J Pharm Biopharm; 2003 Nov; 56(3):421-8. PubMed ID: 14602186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A simulation of the effect of sun reflections from chrome surfaces on visual performance in a variety of viewing situations.
    Duffy W
    Appl Opt; 1969 Sep; 8(9):1803-10. PubMed ID: 20072525
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The law of initial values: a four factor theory.
    Jamieson J; Howk S
    Int J Psychophysiol; 1992 Jan; 12(1):53-61. PubMed ID: 1740402
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Developing Tools to Evaluate Non-linear Mixed Effect Models: 20 Years on the npde Adventure.
    Comets E; Mentré F
    AAPS J; 2021 May; 23(4):75. PubMed ID: 34009502
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Letter to the editor regarding: "a reduction in between subject variability is not mandatory for selecting a new covariate".
    Karlsson MO; Bergstrand M
    J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):725-6; author reply 727. PubMed ID: 23054250
    [No Abstract]   [Full Text] [Related]  

  • 53. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.
    Bergstrand M; Hooker AC; Wallin JE; Karlsson MO
    AAPS J; 2011 Jun; 13(2):143-51. PubMed ID: 21302010
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population pharmacokinetics and dose rationale for aciclovir in term and pre-term neonates with herpes.
    D'Agate S; Ruiz Gabarre D; Della Pasqua O
    Pharmacol Res Perspect; 2024 Jun; 12(3):e1193. PubMed ID: 38775304
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Accelerating drug development for amyotrophic lateral sclerosis: construction and application of a disease course model using historical placebo group data.
    Cai R; Yang J; Wu L; Liu Y; Wang X; Zheng Q; Li L
    Orphanet J Rare Dis; 2024 Feb; 19(1):40. PubMed ID: 38308282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Integrative population pharmacokinetic/pharmacodynamic analysis of nemonoxacin capsule in Chinese patients with community-acquired pneumonia.
    Chen Y; Wu X; Tsai C; Chang L; Yu J; Cao G; Guo B; Shi Y; Zhu D; Hu F; Yuan J; Liu Y; Zhao X; Zhang Y; Wu J; Zhang J
    Front Pharmacol; 2023; 14():912962. PubMed ID: 36923351
    [No Abstract]   [Full Text] [Related]  

  • 57. Mechanism-Based Pharmacokinetic Model for the Deglycosylation Kinetics of 20(S)-Ginsenosides Rh2.
    Ren HC; Sun JG; A JY; Gu SH; Shi J; Shao F; Ai H; Zhang JW; Peng Y; Yan B; Huang Q; Liu LS; Sai Y; Wang GJ; Yang CG
    Front Pharmacol; 2022; 13():804377. PubMed ID: 35694247
    [No Abstract]   [Full Text] [Related]  

  • 58. Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against
    Zhou Y; Zhang J; Chen Y; Wu J; Guo B; Wu X; Zhang Y; Wang M; Ya R; Huang H
    Antibiotics (Basel); 2022 May; 11(5):. PubMed ID: 35625347
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development and Application of the Placebo Response Model in Clinical Trials for Primary Sjögren's Syndrome.
    Wang ZZ; Zheng QS; Liu HX; Li LJ
    Front Immunol; 2021; 12():783246. PubMed ID: 34868062
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population pharmacokinetic and exposure-response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia.
    Gibiansky E; Gibiansky L; Chavanne C; Frey N; Jamois C
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):914-927. PubMed ID: 34110098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.